Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

2Seventy Bio Inc

Company price
None USD 0.00(0%)
Last update at 2025-06-23T13:05:38.379196Z
Market Cap
266.14M

Momentum Score

…

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.29
Low
5.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
48.37M
Revenue Per Share
0.92
Gross Profit TTM
-13.24M
Debt / Equity
1.16
ROE
-1.94%
Net Debt
172.47M
ROCE
-59.83%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -254.15M -292.21M -120.11M -320.59M -199.75M
Net income -254.14M -292.21M -138.17M -323.34M -199.75M
Selling general administrative 79.68M 93.51M 90.90M 81.65M 53.63M
Gross profit 65.28M 52.01M 242.73M 41.32M 53.69M
Reconciled depreciation 11.53M 16.35M 13.19M 12.59M 13.35M
Ebit -262.91M -292.21M -144.64M -337.97M -181.26M
Ebitda -251.14M 16.06M -113.39M -322.64M -167.92M
Depreciation and amortization 11.77M 16.35M 31.24M 15.33M 13.35M
Non operating income net other 6.05M 21.65M - - -
Operating income -262.91M -313.95M -144.64M -337.97M -203.43M
Other operating expenses 354.40M 0.37M 392.76M 382.27M 255.01M
Interest expense 8.51M 276.45M 0.00M 0.00M 15.49M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 2.93M 0.09M - 0.00M -
Net interest income 2.93M 0.09M 0.00M 0.00M -15.49M
Income tax expense -0.01M -313.66M 18.06M 2.75M 19.16M
Total revenue 91.50M 54.52M 248.12M 44.30M 54.58M
Total operating expenses 328.19M 368.47M 387.36M 379.29M 254.12M
Cost of revenue 26.22M 2.52M 5.40M 2.98M 0.89M
Total other income expense net 8.76M 313.66M 24.52M 17.38M 16.16M
Net income from continuing ops -254.15M -292.21M -120.11M -320.59M -199.75M
Net income applicable to common shares -254.15M -292.21M -120.11M -320.59M -199.75M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 479.51M 565.43M 656.66M 759.67M 312.62M
Intangible assets 5.88M 6.59M 7.30M 9.89M 5.64M
Other current assets 12.50M 20.78M 0.01M 26.51M 14.41M
Total liab 268.70M 310.13M 346.20M 399.85M 237.99M
Total stockholder equity 210.81M 255.30M 310.47M 359.82M 74.63M
Other current liab 22.67M 25.69M 58.42M 77.59M 52.58M
Common stock 0.01M 0.01M 0.00M 0.00M 74.63M
Capital stock 0.01M 0.01M 0.00M 0.00M -
Retained earnings -568.46M -511.22M -293.65M -39.49M -
Other liab - - 7.40M 29.02M 49.83M
Good will - 0.00M 12.06M 12.06M 13.13M
Other assets - - 38.39M -0.00M 8.26M
Cash 71.24M 74.96M 71.03M 130.41M -127.60M
Total current liabilities 40.09M 59.78M 79.79M 98.39M 75.87M
Current deferred revenue - 15.40M 3.00M 5.00M 0.82M
Net debt 172.47M 181.72M 199.14M 151.80M 255.21M
Short term debt 16.36M 12.66M 11.16M 9.77M 15.31M
Short long term debt total 243.72M 256.67M 270.17M 282.21M 127.60M
Other stockholder equity 779.18M 766.72M 606.99M 400.03M 74.63M
Property plant equipment - - 55.73M 34.91M 260.48M
Total current assets 187.26M 237.76M 300.88M 291.56M 25.10M
Long term investments 8.87M 4.82M 1.41M 97.12M -
Net tangible assets - - 291.11M 337.87M 55.86M
Short term investments 103.51M 142.03M 195.24M 134.64M -
Net receivables 7.78M 13.41M 20.96M 17.00M 10.69M
Inventory - -13.41M 13.64M -114.12M 127.60M
Accounts payable 1.05M 6.03M 7.21M 6.02M 7.15M
Accumulated other comprehensive income 0.09M -0.20M -2.88M -0.71M -
Common stock total equity - - 0.00M 0.00M -
Retained earnings total equity - - -293.65M -39.49M -
Non currrent assets other 8.87M 36.42M 38.39M 38.59M 8.26M
Non current assets total 292.25M 327.66M 355.78M 468.11M 287.52M
Capital lease obligations 243.72M 256.67M 270.17M 282.21M 127.60M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 34.54M 15.41M -22.26M -59.77M -50.83M
Change to liabilities -7.78M 15.73M -4.92M -2.06M -39.64M
Total cashflows from investing activities 11.70M 15.41M -22.26M -59.77M -50.83M
Net borrowings - - - - -1.02M
Total cash from financing activities 166.23M 354.89M 90.05M 267.72M 197.04M
Change to operating activities -13.44M 9.16M -10.55M 37.21M 35.82M
Net income -254.15M -292.21M -120.11M -320.59M -199.75M
Change in cash -59.21M 163.27M 90.05M 267.72M 197.04M
Begin period cash flow 163.27M 0.00M 0.00M 0.00M 0.00M
End period cash flow 104.06M 163.27M 0.00M 0.00M 0.00M
Total cash from operating activities -237.13M -207.03M -67.79M -207.96M -146.22M
Issuance of capital stock 165.53M - - - -
Depreciation 11.53M 16.35M 13.19M 12.59M 13.35M
Other cashflows from investing activities - -8.00M - - -
Sale purchase of stock 165.53M 354.89M - - -
Other cashflows from financing activities 0.70M 348.35M 90.05M 267.72M 198.06M
Change to netincome 41.36M 55.50M 54.60M 64.91M 44.01M
Capital expenditures 22.84M 19.57M 22.26M 59.77M 50.83M
Cash flows other operating -28.09M -2.40M - - -
Cash and cash equivalents changes -59.21M 163.27M - - -
Change in working capital -35.87M 13.33M -15.47M 35.14M -3.82M
Stock based compensation 41.04M 54.63M 61.00M 62.05M 40.80M
Other non cash items 0.32M 0.87M -6.39M 2.86M 3.21M
Free cash flow -259.98M -226.61M -90.05M -267.72M -197.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

2Seventy Bio Inc

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

60 Binney Street, Cambridge, MA, United States, 02142

617 675 7270

65

Name Title Year Born
Mr. Nick Leschly Pres, CEO & Director 1973
Mr. William D. Baird III Chief Financial Officer 1972
Ms. Nicola H. Heffron Chief Operating Officer 1973
Ms. Susan Abu-Absi Ph.D. Chief Technology & Manufacturing Officer NA
Dr. Philip D. Gregory D. Phil., DPHIL Chief Scientific Officer 1971
Ms. Teresa L. Jurgensen J.D. VP, Gen. Counsel & Corp. Sec. NA
Ms. Kathleen A. Wilkinson Head of People & Culture 1972
Mr. Kevin Chin M.D., M.S. Head of Clinical Devel. NA
Mr. Steven Shamah Ph.D. Head of Oncology Research NA
Ms. Jenn Snyder Head of Corp. Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…